Regeneron Q3 2021 Earnings Report
Key Takeaways
Regeneron reported a strong third quarter in 2021, with total revenues increasing by 51% to $3.45 billion compared to the third quarter of 2020. GAAP diluted EPS was $14.33 and non-GAAP diluted EPS was $15.37. The company saw growth in EYLEA U.S. net sales and Dupixent global net sales.
Third quarter revenues increased 51% to $3.45 billion versus third quarter 2020, including $804 million attributable to REGEN-COV.
EYLEA U.S. net sales increased 12% versus third quarter 2020 to $1.47 billion.
Dupixent global net sales increased 55% to $1.66 billion versus third quarter 2020.
GAAP diluted EPS was $14.33 and non-GAAP diluted EPS was $15.37.
Regeneron
Regeneron
Regeneron Revenue by Segment
Forward Guidance
Regeneron's full year 2021 financial guidance includes estimates for R&D, SG&A, gross margin on net product sales, COCM, other operating expense, capital expenditures, and effective tax rate.